Get the Stockscreener App
11.36
0.35%
-0.04
After Hours:
11.36
Roivant Sciences Ltd stock is traded at $11.36, with a volume of 3.55M.
It is down -0.35% in the last 24 hours and up +0.80% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$11.40
Open:
$11.3
24h Volume:
3.55M
Relative Volume:
0.60
Market Cap:
$7.72B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
2.0106
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-0.18%
1M Performance:
+0.80%
6M Performance:
+2.07%
1Y Performance:
+4.70%
1-Day Range:
$11.26
$11.51
1-Week Range:
$11.26
$11.64
52-Week Range:
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.36 | 7.78B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Should I hold or sell Roivant Sciences Ltd. stock in 2025Chart Pattern Growth Plan For Every Investor - jammulinksnews.com
Is it the right time to buy Roivant Sciences Ltd. stockTop Growth Review With High Returns - jammulinksnews.com
Why is Roivant Sciences Ltd. stock attracting strong analyst attentionReal Time Ideas With Low Risk - jammulinksnews.com
What are analysts’ price targets for Roivant Sciences Ltd. in the next 12 monthsValue Investing Data Feed For Beginners - jammulinksnews.com
How does Roivant Sciences Ltd. generate profit in a changing economySwing Trade Updates To Watch Now - jammulinksnews.com
Recovery Signals Appearing in Roivant Sciences Ltd. ChartsConsistent Income Focused Trade List Analyzed - metal.it
Is Roivant Sciences Ltd. Starting a New UptrendReal-Time Trade Insights Spark Market Reactions - metal.it
What caused the surprising earnings drop in Q2 2025 for ROIV? - AInvest
Published on: 2025-07-29 10:36:14 - metal.it
Roivant Sciences Ltd. Consolidation Zone May Signal AccumulationChart Driven High Reward Trading Setup Presented - metal.it
Roivant to Reveal Q1 2025 Financial Performance and Strategic Updates: Key Details for August 11 Earnings Call - Stock Titan
What is the risk reward ratio of investing in Roivant Sciences Ltd. stockUnlock exclusive stock market forecasts - jammulinksnews.com
Is Roivant Sciences Ltd. a growth stock or a value stockChart Pattern Ideas For Fast Growth - jammulinksnews.com
What is the dividend policy of Roivant Sciences Ltd. stockCapitalize on trading strategies that deliver - jammulinksnews.com
How volatile is Roivant Sciences Ltd. stock compared to the marketBuild a portfolio that outperforms the market - jammulinksnews.com
Published on: 2025-07-28 06:27:01 - jammulinksnews.com
Is Roivant Sciences Ltd. a Top Dividend Stock to Watch in 2025High Return Conservative Stocks - metal.it
Published on: 2025-07-27 16:10:26 - jammulinksnews.com
Is Roivant Sciences Ltd. a good long term investmentUnbelievable profit margins - Autocar Professional
Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News - GuruFocus
Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating - MSN
Vivek Ramaswamy to welcome third child soon: Meet his wife and his two elder sons - The Times of India
Roivant Sciences Ltd. Stock Analysis and ForecastFree Stock Market Beginners Guide - Autocar Professional
Roivant Sciences’ president Venker sells $1.15 million in shares By Investing.com - Investing.com South Africa
Roivant Sciences’ president Venker sells $1.15 million in shares - Investing.com Australia
Roivant Sciences President Eric Venker Sells 100k Shares at $11.52, Buys 100k at $3.85. - AInvest
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey
What drives Roivant Sciences Ltd. stock priceExceptional risk-adjusted gains - jammulinksnews.com
What analysts say about Roivant Sciences Ltd. stockTriple-digit profit margins - jammulinksnews.com
(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com
Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating By Investing.com - Investing.com South Africa
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):